ATE133267T1 - Durch protoonkogenischen proteinkomplex ap-1 kontrollierte verfahren - Google Patents
Durch protoonkogenischen proteinkomplex ap-1 kontrollierte verfahrenInfo
- Publication number
- ATE133267T1 ATE133267T1 AT91917435T AT91917435T ATE133267T1 AT E133267 T1 ATE133267 T1 AT E133267T1 AT 91917435 T AT91917435 T AT 91917435T AT 91917435 T AT91917435 T AT 91917435T AT E133267 T1 ATE133267 T1 AT E133267T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- date
- glucocorticoid
- genes
- repress
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58618790A | 1990-09-21 | 1990-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE133267T1 true ATE133267T1 (de) | 1996-02-15 |
Family
ID=24344674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91917435T ATE133267T1 (de) | 1990-09-21 | 1991-09-20 | Durch protoonkogenischen proteinkomplex ap-1 kontrollierte verfahren |
Country Status (11)
Country | Link |
---|---|
US (1) | US5639592A (de) |
EP (1) | EP0552202B2 (de) |
JP (1) | JPH06503642A (de) |
AT (1) | ATE133267T1 (de) |
AU (1) | AU655943B2 (de) |
CA (1) | CA2090407A1 (de) |
DE (1) | DE69116563T3 (de) |
DK (1) | DK0552202T3 (de) |
ES (1) | ES2082231T3 (de) |
GR (1) | GR3018708T3 (de) |
WO (1) | WO1992005447A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7675491A (en) | 1990-04-04 | 1991-10-30 | Chiron Corporation | Hepatitis c virus protease |
US6004748A (en) * | 1990-10-10 | 1999-12-21 | La Jolla Cancer Research Foundation | Method of inhibiting transcription utilizing nuclear receptors |
US6683047B1 (en) | 1990-10-10 | 2004-01-27 | The Burnham Institute | Method of inhibiting transcription utilizing nuclear receptors |
AU8946991A (en) * | 1990-10-10 | 1992-05-20 | La Jolla Cancer Research Foundation | Method of inhibiting transcription utilizing nuclear receptors |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
US20050084885A1 (en) * | 1994-01-18 | 2005-04-21 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
GB9601042D0 (en) * | 1996-01-17 | 1996-03-20 | Smithkline Beecham Plc | Medical use |
GB9414157D0 (en) * | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Medical use |
EP2022856B1 (de) | 1994-08-20 | 2011-09-14 | Gendaq Limited | Verbesserungen bei oder im Zusammenhang mit Bindeproteinen zur Erkennung von DNA |
GB9420735D0 (en) * | 1994-10-14 | 1994-11-30 | Karobio Ab | Reporter cell line |
US6489441B1 (en) * | 1995-09-01 | 2002-12-03 | The Salk Institute For Biological Studies | Transcriptional co-repressor that interacts with nuclear hormone receptors |
WO1997010813A1 (en) | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
AU732149B2 (en) * | 1997-06-17 | 2001-04-12 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | AIB1, a novel steroid receptor co-activator |
AU8526198A (en) * | 1997-08-01 | 1999-02-22 | Universite De Montreal | Compounds with anti-ks and anti-hiv activity |
US6852496B1 (en) * | 1997-08-12 | 2005-02-08 | Oregon Health And Science University | Methods of screening for agents that promote nerve cell growth |
AU757348B2 (en) * | 1997-09-04 | 2003-02-20 | Regents Of The University Of California, The | Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
EP1060261B1 (de) * | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
US6977154B1 (en) | 1998-03-17 | 2005-12-20 | Gendaq Limited | Nucleic acid binding proteins |
WO1999062507A1 (en) | 1998-06-02 | 1999-12-09 | Arthromics Plc | Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
US6140081A (en) * | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) * | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7013219B2 (en) * | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US20030104526A1 (en) * | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US6734211B1 (en) | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
WO2001040798A2 (en) | 1999-12-06 | 2001-06-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
ES2436610T3 (es) | 2000-01-21 | 2014-01-03 | Novartis Ag | Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos |
WO2001053480A1 (en) * | 2000-01-24 | 2001-07-26 | Sangamo Biosciences, Inc. | Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules |
JP2004537260A (ja) * | 2000-12-07 | 2004-12-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | ジンクフィンガータンパク質による血管新生の調節 |
US7067317B2 (en) * | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
CA2435394C (en) * | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
US7067617B2 (en) * | 2001-02-21 | 2006-06-27 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
KR20030046896A (ko) * | 2001-12-07 | 2003-06-18 | 학교법인 포항공과대학교 | 당질코르티코이드에 의해 발현이 조절되는 재조합 리포터유전자를 가지는 형질전환 세포주 및 이를 이용한당질코르티코이드 유사물질 및 저해물질의 생물학적검색방법 |
US7262054B2 (en) * | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
EP1388352A1 (de) | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden |
US7361635B2 (en) * | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
PL1931350T5 (pl) | 2005-09-14 | 2021-11-15 | Takeda Pharmaceutical Company Limited | Podanie inhibitorów dipeptydylo-peptydazy |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
CA2787360C (en) | 2010-02-03 | 2019-03-05 | Takeda Pharmaceutical Company Limited | Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors |
JP2023549132A (ja) * | 2020-11-06 | 2023-11-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 転写因子-化学的誘導近接(tf-cip)による遺伝子発現の調節方法 |
-
1991
- 1991-09-20 ES ES91917435T patent/ES2082231T3/es not_active Expired - Lifetime
- 1991-09-20 US US08/030,330 patent/US5639592A/en not_active Expired - Fee Related
- 1991-09-20 DK DK91917435.9T patent/DK0552202T3/da active
- 1991-09-20 CA CA002090407A patent/CA2090407A1/en not_active Abandoned
- 1991-09-20 AU AU86309/91A patent/AU655943B2/en not_active Ceased
- 1991-09-20 JP JP3516072A patent/JPH06503642A/ja active Pending
- 1991-09-20 WO PCT/US1991/006848 patent/WO1992005447A1/en active IP Right Grant
- 1991-09-20 AT AT91917435T patent/ATE133267T1/de not_active IP Right Cessation
- 1991-09-20 EP EP91917435A patent/EP0552202B2/de not_active Expired - Lifetime
- 1991-09-20 DE DE69116563T patent/DE69116563T3/de not_active Expired - Fee Related
-
1996
- 1996-01-18 GR GR950402161T patent/GR3018708T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU8630991A (en) | 1992-04-15 |
JPH06503642A (ja) | 1994-04-21 |
EP0552202B1 (de) | 1996-01-17 |
DE69116563T3 (de) | 2006-07-06 |
ES2082231T3 (es) | 1996-03-16 |
US5639592A (en) | 1997-06-17 |
AU655943B2 (en) | 1995-01-19 |
EP0552202A1 (de) | 1993-07-28 |
DE69116563T2 (de) | 1996-07-04 |
GR3018708T3 (en) | 1996-04-30 |
CA2090407A1 (en) | 1992-03-22 |
EP0552202B2 (de) | 2005-09-28 |
DK0552202T3 (da) | 1996-06-03 |
DE69116563D1 (de) | 1996-02-29 |
WO1992005447A1 (en) | 1992-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE133267T1 (de) | Durch protoonkogenischen proteinkomplex ap-1 kontrollierte verfahren | |
Huang et al. | A novel role for bone morphogenetic proteins in the synthesis of follicle-stimulating hormone | |
Johnson et al. | Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from the mitogenic response. | |
Zhu et al. | Role of transcription factor TFIIF in serum response factor-activated transcription. | |
Tomic-Canic et al. | Novel Regulation of Keratin Gene Expression by Thyroid Hormone and Retinoid Receptors (∗) | |
DK0760857T5 (da) | Receptor for onkostatin M | |
NO962991L (no) | Zink-finger-proteinderivater og fremgangsmåter derav | |
DE69129990D1 (de) | Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor | |
DE122004000041I1 (de) | Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor. | |
EP0550592A4 (en) | Screening assays | |
DE69029812D1 (de) | Elemente für retinsäureantwortzusammensetzung und nachweisverfahren | |
Salkowski et al. | IFN-gamma mediates increased glucocorticoid receptor expression in murine macrophages. | |
NO955011L (no) | Intracellulære bindingsproteiner og deres anvendelse | |
DE69314024T2 (de) | NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE | |
FR2706618B1 (fr) | Dispositif pour le dosage d'haptènes et son utilisation. | |
ATE217649T1 (de) | Synthetische eukaryotische promotoren welche zwei induzierbare elemente enthalten | |
Klocker et al. | Mechanism of androgen receptor activation and possible implications for chemoprevention trials | |
DE69636013D1 (de) | Verfahren zum erlangen von rezeptor-freigabeligand (reland)-komplexen und testansätze | |
Koelle | Molecular analysis of the Drosophila ecdysone receptor complex | |
Meinkoth et al. | Inhibition of thyrotropin-induced DNA synthesis in thyroid follicular cells by microinjection of an antibody to the stimulatory G protein of adenylate cyclase, Gs. | |
Ivell et al. | Acute regulation of the bovine gene for the steroidogenic acute regulatory protein in ovarian theca and adrenocortical cells | |
DE69304528T2 (de) | Verfahren zur bestimmung der menge eines schilddrüsenhormon-liganden in einer biologischen flüssigkeit und satz zur durchführung dieses verfahrens | |
CA2093811A1 (en) | Method of inhibiting transcription utilizing nuclear receptors | |
DE68927480D1 (de) | Für die gamma-untereinheit des rezeptors mit hoher affinität für immunglobulin e kodierende cdnas | |
Henderson et al. | GATA elements are necessary for the activity and tissue specificity of the T-cell receptor beta-chain transcriptional enhancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |